Charles Schwab Investment Management Inc Aveo Pharmaceuticals, Inc. Transaction History

Charles Schwab Investment Management Inc

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	SELL	$6.61 - $8.72 $39,673 - $52,337	-6,002 Reduced 34.94%	11,178 $92,000
Q3 2021 Nov 16, 2021	BUY	$5.12 - $6.89 $87,961 - $118,370	17,180 New	17,180 $107,000
Q2 2021 Aug 16, 2021	SELL	$6.21 - $7.45 $343,301 - $411,850	-55,282 Closed	0 $0
Q1 2021 May 17, 2021	SELL	$5.97 - $15.28 $15,414 - $39,452	-2,582 Reduced 4.46%	55,282 $405,000
Q4 2020 Feb 16, 2021	BUY	$5.08 - $6.68 $49,372 - $64,922	9,719 Added 20.19%	57,864 $334,000
Q3 2020 Nov 13, 2020	BUY	$4.16 - $6.26 $66,293 - $99,759	15,936 Added 49.48%	48,145 $286,000
Q2 2020 Aug 14, 2020	BUY	$3.47 - $9.99 $111,765 - $321,767	32,209 New	32,209 $166,000

Ticker AVEO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 34,676,000
Description
AVEO Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing and commercializing medicines for cancer patients. It markets its lead candidate, FOTIVDA, an oral, once-daily, vascular endothelial growth factor receptor tyrosine kinase inhibitor, which is used for the treatment of renal cell carcinoma (RCC); and tivozanib for the ...

Get notified when there are updates to the investment portfolio of Charles Schwab Investment Management Inc, based on Form 13F filings with the SEC.

Stay updated on Charles Schwab Investment Management Inc with notifications on news.